Vizient Medical Device Tech Watch Highlights Rapid Adoption of AI-Enabled Stroke Detection

Data analysis from the Vizient, Inc. Clinical Data Base shows a rapid uptake in the use of artificial intelligence (AI) for detection of ischemic stroke. The data is highlighted in the latest edition of Vizient’s Medical Device Tech Watch. In addition, the publication offers insights on the shift of spine and orthopedics from hospital inpatient to ambulatory surgery centers as well as a perspective on improving surgical preference card management. The publication can be accessed here.

“This year has brought about many opportunities to partner strategically and collaborate across organizations to tackle obstacles in health care,” said Erik Axter, managing principal, physician preference, Vizient. “We are excited about the new technologies and solutions emerging to help solve these challenges and advance our industry, particularly in complex categories like cardiology and orthopedics.”

Featured articles include:

AI-enabled ischemic stroke detection, triage and notification—Quick intervention for an intracranial large-vessel occlusion (LVO), a common type of ischemic stroke, can improve patient outcomes. With the AI process, an interventionalist could conceivably receive the LVO image on their mobile phone, evaluate the scan and begin booking the procedure immediately. On October 1, 2020, the Centers for Medicare & Medicaid Services (CMS) implemented a reimbursement policy for AI-based LVO detection. By the first quarter of 2021, analysis of the Vizient Clinical Data Base showed, the number of Vizient members using the AI technology doubled.

The shift to ambulatory orthopedic and spine procedures moves suppliers to ramp up provider support—ASC procedural volume continues to accelerate, fueled by CMS policy changes, commercial payer steerage, patient preference and pressure to reduce costs. Data from Sg2, a Vizient company, predicts outpatient hip and knee replacements to increase by 75% over the next several years. Manufacturers are responding to the current and future growth by expanding their service line and technology offerings to support ASC performance.

How one health system improved supply availability and accuracy by optimizing their surgical preference card database—Inaccurate surgical preference cards were negatively affecting surgeon and staff satisfaction and slowing turnaround times in the OR of a large academic medical. To address this issue, they developed a sustainable process for managing the cards, increasing staff confidence in their accuracy and ensuring the OR is properly equipped prior to each procedure, improving efficiency as well as patient safety.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”